RFK Jr’s FDA Overhaul: Agency Stacks Peptide Panel With Doctors Tied to Unregulated Industry
The Food and Drug Administration has released the participant list for an upcoming July panel on peptide drugs — and the roster marks a sharp departure from prior reviews, drawing almost entirely from practitioners and promoters rather than independent researchers, according to the agency’s own announcement Monday.
A Panel Remade in RFK Jr.’s Image
Health and Human Services Secretary Robert F. Kennedy Jr. and his deputies have spent months publicly assailing federal expert panels as compromised by pharmaceutical industry influence. Now, the administration is replacing those panels with voices from the very wellness industry the peptides business has spawned. The new group includes doctors and pharmacists who prescribe, produce or promote peptide formulas — the same compounds set for review.
“We are seeing the fox appointed to guard the henhouse,” said Dr. Marcus Hoffmann, an endocrinologist at NYU Langone who has served on prior FDA compounding panels. “The people deciding whether these products are safe are the same people selling them.”
The two-day July meeting will evaluate seven peptide compounds, including BPC-157 and TB-500 — injectable substances that have attracted intense interest from athletes, influencers and wellness clinics despite limited evidence of benefit in humans. International sports authorities have designated both as doping substances.
Safety Worries in an Unregulated Market
The FDA has warned Americans for several years against injecting peptides with names like BPC-157 and TB-500, noting that neither has undergone extensive human study. Compounding pharmacies serve as the primary domestic source for many of these products, operating under labeling rules that sidestep conventional FDA approval pathways.
Sellers typically market the compounds as “for research use only,” exploiting a regulatory gray zone the agency has struggled to close. The substances are widely available online and promoted for uses ranging from muscle building to injury recovery to anti-aging — claims unsupported by large-scale clinical trials.
“This is the Wild West of bioregulatory supplements,” said Dr. Priya Nair, a pharmacologist at Johns Hopkins Bloomberg School of Public Health. “When you eliminate independent oversight and replace it with the people who profit from the products, patient safety becomes a secondary concern.”
Previous FDA compounding panels composed of academic researchers and independent toxicologists voted against every peptide ingredient brought forward by compounding pharmacies, deeming each too risky for patient use. The new panel’s composition suggests those outcomes are unlikely to repeat.
What Comes Next
The peptide trend gained momentum after Kennedy, a longtime critic of the pharmaceutical industry, was appointed HHS Secretary and began publicly endorsing wellness alternatives to conventional medicine. His “Make America Healthy Again” platform has championed compounds that mainstream medicine has treated with skepticism, including peptides marketed for uses extending well beyond any approved indication.
The FDA’s decision to exclude academic researchers from the review panel marks a significant break from standard scientific practice. Agency records show that every peptide ingredient previously submitted for evaluation was rejected by independent panels citing insufficient safety data and the absence of randomized clinical trials supporting therapeutic claims.
The July panel recommendations are expected to carry significant weight in determining whether peptides remain readily available to U.S. consumers or face new restrictions. With the domestic market estimated at several hundred million dollars annually, the stakes for manufacturers and patients alike are considerable. Watchdog groups say the outcome will serve as a test case for how far the administration is willing to reshape scientific review to fit a political agenda, and whether the FDA can still function as an independent guardian of public health. Consumer advocates warn that a favorable ruling for the peptide industry could expose millions of Americans to products with unknown long-term safety profiles, setting back the agency’s efforts to regulate compounded biologics for a generation.
